TheratOcular

TheratOcular Biotherapeutics is a pre-clinical stage biotechnology company dedicated to developing next-generation biologics for the treatment of retinal diseases. The company leverages a proprietary protein engineering platform to design multi-functional therapeutic proteins that address complex pathologies in conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. By focusing on improved durability and superior efficacy compared to current standard-of-care anti-VEGF treatments, TheratOcular aims to reduce the treatment burden for patients with chronic ocular conditions. Their pipeline includes innovative candidates designed to simultaneously inhibit multiple disease pathways, including angiogenesis and inflammation.